Download PDFPDF

Weaning strategy with inhaled nitric oxide treatment in persistent pulmonary hypertension of the newborn
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Measurement of methaemoglobin levels in babies
    Dear Editor,

    Nitric oxide (NO) is frequently used as a selective pulmonary vasodilator in neonates. Since its metabolite, methaemoglobin can potentially cause tissue hypoxia it is considered mandatory to measure methaemoglobin levels when using NO. In an attempt to review and rationalise our own practice of methaemoglobin measurement when using NO we undertook a search of current literature and conducted a postal surv...

    Show More
    Conflict of Interest:
    None declared.